search
Back to results

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Aerovant
Aerovant
Aerovant
placebo
Sponsored by
Aerovance, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring asthma, allergy, atopy, atopic, wheeze

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female patient, ≥ 18 years of age with a documented clinical history of asthma, has been treated for asthma and, in the opinion of the Investigator, is not fully controlled on current asthma therapy.
  2. Patient satisfies, or has satisfied in the past, the GINA definition of moderate persistent to severe persistent asthma.
  3. Patient has been maintained on moderate-to-high doses of ICS and LABA in the form of combination therapy or as individual agents (equivalent to fluticasone ≥ 250 mcg bid and salmeterol ≥ 50 mcg bid for ≥ 4 weeks before Screening [Visit 1]).
  4. Patient has experienced an asthma exacerbation at least once in the past 2 years (defined here as use of physician prescribed oral corticosteroids or asthma requiring treatment increase approximately 4 times the baseline dose of inhaled corticosteroids or hospitalization due to asthma).
  5. Patient has a pre-bronchodilator FEV1 ≥ 50% but ≤ 95% of the predicted value at both Screening (Visit 1) and Visit 2.
  6. Patient demonstrates ≥ 12% reversibility (and a ≥ 200 mL difference) from prebronchodilator FEV1 within 15 to 30 minutes of receiving up to 4 puffs of a short-acting beta-agonist at Screening (Visit 1) or has ≥ 10% reversibility from pre-bronchodilator FEV1 plus a documented reversibility of ≥ 12% within the previous 12 months (documented methacholine or histamine sensitivity (PC20) <8mg/mL is also acceptable evidence or reversible airways disease).
  7. Patient scores ≤ 20 on The Asthma Control Test™ at Screening (Visit 1) and Visit 2.
  8. Female patient of childbearing potential or male patient and his female partner are practicing adequate and effective forms of contraception and agree to continue for the duration of the study. If female, must have a negative urine pregnancy test.
  9. Patient has a pre-study medical history, physical examination, 12-Lead ECG, and safety laboratory test results within normal reference ranges or clinically acceptable to the Investigator.
  10. Patient is a non-smoker for at least 6 months before Screening (Visit 1) and has a < 10 pack/year history of smoking.
  11. Patient is medically stable for at least 8 weeks before Randomization (Visit 2), and the Investigator does not consider study participation to place the patient at increased risk of AEs (with the exception of possible asthma exacerbations).
  12. Patient is able and willing to give written informed consent.

Exclusion Criteria:

  1. Patient has a current diagnosis of respiratory disorder other than asthma (e.g., chronic bronchitis, bronchiectasis, emphysema, chronic obstructive pulmonary disease [COPD], etc).
  2. Patient has received oral corticosteroid treatment within 8 weeks of Randomization (Visit 2)or patient has been intubated for ventilation in the past 5 years.
  3. Patient has used any leukotriene antagonist within 1 week before Screening (Visit 1) or anti-IgE medications within 4 weeks of Screening (Visit 1).
  4. Female patient is pregnant, breastfeeding, or not using an adequate method of contraception.
  5. Patient has a clinically relevant medical history of very severs asthma that would preclude steroid reduction or sufficient compliance with the protocol.
  6. Patient uses concomitant medications, including herbal, over-the-counter, or prescription medicines that, in the opinion of the Investigator, may affect the outcome of study endpoints and/or well-being of the patient.
  7. Patient has a history of alcohol or substance abuse within 2 years of Screening (Visit 1).
  8. Patient consumes more than 28 units (male) or 21 units (female) of alcohol a week (unit = 1 glass of wine = 1measure of spirits = ½ pint or 8 fluid ounces of beer).
  9. Patient cannot communicate reliably with the Investigator or is unlikely to cooperate with the requirements of the study.
  10. Patient has previously taken AEROVANT™ or another formulation of AER 001 (e.g., BAY 16-9996, pitrakinra).
  11. Patient has participated in any clinical trial involving use of an investigational drug within 12 weeks of first dose of study drug.

Sites / Locations

  • Pulmonary Associates of Mobile, P.C.
  • Allergy and Immunology Associates Ltd
  • Allergy and Asthma Specialists Medical Group
  • Allergy Associates Medical Group Inc.
  • Institute of Healthcare Assessment Inc.
  • Allergy and Asthma Associates of Santa Clara Valley Research Center
  • Allergy and Asthma Clinical Research Inc.
  • Colorado Asthma and Allergy Research Centers, P.C.
  • Asthma and Allergy Associates P.C. and Research Center
  • National Jewish Health
  • Florida Center for Asthma and Allergy Research
  • Allergy and Asthma Diagnostic Treatment Center
  • Partners in Asthma and Allergy Care, P.A.
  • Pulmonary Consultants of North Idaho
  • Deaconess Clinic Downtown
  • Allergy and Clinical Immunology
  • The Brigham and Womens Hospital Inc.
  • North East Medical Research Associates, Inc
  • Cardiopulmonary Associates of Missoula
  • Pulmonary and Allergy Associates
  • ENT and Allergy Associates
  • Wake Forest University
  • New Horizons Clinical Research
  • Bernstein Clinical Research Center
  • Allergy, Asthma and Clinical Research Center
  • IPS Research
  • Allergy and Asthma Associates/Oak Street Medical P.C.
  • Allergy Associates Research Center
  • Asthma and Allergy Research of New Jersey Inc.
  • University of Pittsburgh Medical Center
  • Asthma and Allergy Research Associates, PA
  • Asthma, Nasal Disease and Allergy Research Center of New England
  • Greenville Pharmaceutical Research
  • Spartanburg Medical Research
  • Baylor College of Medicine
  • Allergy and Asthma Research Center, P.A.
  • Discovery Clinical Trials, LLC
  • Johnston Memorial Hospital
  • Dr. Kenessey Albert Kórház - Rendelőintézet
  • Gyógyír XI Kht ( XI Kerületi Tüdőgondozó)
  • Margit Kórház
  • Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza
  • Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktató Kórház
  • Siofok Varos Korhaz-Rendelointezet
  • Szarvasi Tüdőgyógyász Kft.
  • Men For Care Kft. Százhalom Egészségügyi Központ
  • Vas Megyei Markusovszky Lajos Általános, Rehabilitációs és Gyógyfürdő Kórház
  • Komárom-Esztergom Megyei Önkormányzat Szent Borbála Kórháza
  • Érd Városi Önkormányzat Szakorvosi Rendelőintézet
  • Prywatny Gabinet Internistyczno - Alergologiczny
  • 10 Wojskowy Szpital Kliniczny z Poliklinika Kliniczny Oddzial Pulmonologiczny
  • Specjalistyczny Zespol Chorob Pluc i Gruzlicy w Bystrej
  • Medcare NZOZ
  • All-Med
  • NZOZ Centrum Alergologii prof. Krzysztof Buczylko
  • Poradnia Alergologii i Chorob Pluc SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlicki
  • AlergoTest SC
  • NZOZ Centrum Medyczne Lucyna Andrzej Dymek
  • Alergomed Specjalistyczna Przychodnia Lekarska sp zoo
  • Barnsley District Hospital
  • Birmingham Heartlands Hospital
  • Queens Hospital
  • Woolpit Health Centre
  • Addenbrookes Hospital
  • Avondale Surgery
  • Chesterfield Royal Hospital
  • Colchester General Hospital
  • Gartnavel General Hospital
  • Glenfield Hospital
  • Hammersmith Hospital
  • Morriston Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Aerovant 1

Aerovant 2

Aerovant 3

Placebo Control

Arm Description

Aerovant 1mg bid

Aerovant 3mg bid

Aerovant 10mg bid

Placebo Control

Outcomes

Primary Outcome Measures

Incidence of exacerbation

Secondary Outcome Measures

In-clinic and daily pulmonary function
Time to exacerbation after randomization
Change from baseline in daily asthma symptom scores
Change from baseline in daily beta-agonist reliever use
Change from baseline in total IgE
Change from baseline in fractional concentration of expired nitric oxide (FENO)
Population pharmacokinetics
General safety evaluation including lung function, blood pressure, heart rate, respiratory rate, temperature, ECG parameters, safety laboratory tests.
SNP analysis for IL-4 and IL-13 relevant genes (Exploratory)

Full Information

First Posted
December 1, 2008
Last Updated
January 25, 2011
Sponsor
Aerovance, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00801853
Brief Title
A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL
Official Title
A Phase IIb Study to Investigate the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients Not Fully Controlled on Current Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
November 2009
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Aerovance, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A multi-center, Phase IIb, double-blind, randomized, placebo controlled, parallel-group, repeated-dose study in male and female patients with moderate to severe asthma in which patients will be stabilized on AEROVANT then doses of inhaled corticosteroids and LABA will be tapered. The hypothesis is that AEROVANT will improve asthma symptom control and decrease the need for inhaled corticosteroids and LABA, thus improving exacerbation incidence compared to placebo. Incidence of asthma exacerbation is the primary endpoint.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
asthma, allergy, atopy, atopic, wheeze

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
424 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Aerovant 1
Arm Type
Experimental
Arm Description
Aerovant 1mg bid
Arm Title
Aerovant 2
Arm Type
Experimental
Arm Description
Aerovant 3mg bid
Arm Title
Aerovant 3
Arm Type
Experimental
Arm Description
Aerovant 10mg bid
Arm Title
Placebo Control
Arm Type
Placebo Comparator
Arm Description
Placebo Control
Intervention Type
Drug
Intervention Name(s)
Aerovant
Other Intervention Name(s)
AER 001 DPI, BAY 16-9996, pitrakinra
Intervention Description
Aerovant 1mg bid (dry powder)
Intervention Type
Drug
Intervention Name(s)
Aerovant
Other Intervention Name(s)
AER 001 DPI, BAY 16-9996, pitrakinra
Intervention Description
Aerovant 3mg bid (dry powder)
Intervention Type
Drug
Intervention Name(s)
Aerovant
Other Intervention Name(s)
AER 001 DPI, BAY 16-9996, pitrakinra
Intervention Description
Aerovant 10mg bid (dry powder)
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
placebo control (dry powder)
Primary Outcome Measure Information:
Title
Incidence of exacerbation
Time Frame
4 months
Secondary Outcome Measure Information:
Title
In-clinic and daily pulmonary function
Time Frame
4 months
Title
Time to exacerbation after randomization
Time Frame
4 months
Title
Change from baseline in daily asthma symptom scores
Time Frame
4 months
Title
Change from baseline in daily beta-agonist reliever use
Time Frame
4 months
Title
Change from baseline in total IgE
Time Frame
4 months
Title
Change from baseline in fractional concentration of expired nitric oxide (FENO)
Time Frame
4 months
Title
Population pharmacokinetics
Time Frame
4 months
Title
General safety evaluation including lung function, blood pressure, heart rate, respiratory rate, temperature, ECG parameters, safety laboratory tests.
Time Frame
4 months
Title
SNP analysis for IL-4 and IL-13 relevant genes (Exploratory)
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient, ≥ 18 years of age with a documented clinical history of asthma, has been treated for asthma and, in the opinion of the Investigator, is not fully controlled on current asthma therapy. Patient satisfies, or has satisfied in the past, the GINA definition of moderate persistent to severe persistent asthma. Patient has been maintained on moderate-to-high doses of ICS and LABA in the form of combination therapy or as individual agents (equivalent to fluticasone ≥ 250 mcg bid and salmeterol ≥ 50 mcg bid for ≥ 4 weeks before Screening [Visit 1]). Patient has experienced an asthma exacerbation at least once in the past 2 years (defined here as use of physician prescribed oral corticosteroids or asthma requiring treatment increase approximately 4 times the baseline dose of inhaled corticosteroids or hospitalization due to asthma). Patient has a pre-bronchodilator FEV1 ≥ 50% but ≤ 95% of the predicted value at both Screening (Visit 1) and Visit 2. Patient demonstrates ≥ 12% reversibility (and a ≥ 200 mL difference) from prebronchodilator FEV1 within 15 to 30 minutes of receiving up to 4 puffs of a short-acting beta-agonist at Screening (Visit 1) or has ≥ 10% reversibility from pre-bronchodilator FEV1 plus a documented reversibility of ≥ 12% within the previous 12 months (documented methacholine or histamine sensitivity (PC20) <8mg/mL is also acceptable evidence or reversible airways disease). Patient scores ≤ 20 on The Asthma Control Test™ at Screening (Visit 1) and Visit 2. Female patient of childbearing potential or male patient and his female partner are practicing adequate and effective forms of contraception and agree to continue for the duration of the study. If female, must have a negative urine pregnancy test. Patient has a pre-study medical history, physical examination, 12-Lead ECG, and safety laboratory test results within normal reference ranges or clinically acceptable to the Investigator. Patient is a non-smoker for at least 6 months before Screening (Visit 1) and has a < 10 pack/year history of smoking. Patient is medically stable for at least 8 weeks before Randomization (Visit 2), and the Investigator does not consider study participation to place the patient at increased risk of AEs (with the exception of possible asthma exacerbations). Patient is able and willing to give written informed consent. Exclusion Criteria: Patient has a current diagnosis of respiratory disorder other than asthma (e.g., chronic bronchitis, bronchiectasis, emphysema, chronic obstructive pulmonary disease [COPD], etc). Patient has received oral corticosteroid treatment within 8 weeks of Randomization (Visit 2)or patient has been intubated for ventilation in the past 5 years. Patient has used any leukotriene antagonist within 1 week before Screening (Visit 1) or anti-IgE medications within 4 weeks of Screening (Visit 1). Female patient is pregnant, breastfeeding, or not using an adequate method of contraception. Patient has a clinically relevant medical history of very severs asthma that would preclude steroid reduction or sufficient compliance with the protocol. Patient uses concomitant medications, including herbal, over-the-counter, or prescription medicines that, in the opinion of the Investigator, may affect the outcome of study endpoints and/or well-being of the patient. Patient has a history of alcohol or substance abuse within 2 years of Screening (Visit 1). Patient consumes more than 28 units (male) or 21 units (female) of alcohol a week (unit = 1 glass of wine = 1measure of spirits = ½ pint or 8 fluid ounces of beer). Patient cannot communicate reliably with the Investigator or is unlikely to cooperate with the requirements of the study. Patient has previously taken AEROVANT™ or another formulation of AER 001 (e.g., BAY 16-9996, pitrakinra). Patient has participated in any clinical trial involving use of an investigational drug within 12 weeks of first dose of study drug.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sally Wenzel, M.D.
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pulmonary Associates of Mobile, P.C.
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
Allergy and Immunology Associates Ltd
City
Scottsdale
State/Province
Arizona
Country
United States
Facility Name
Allergy and Asthma Specialists Medical Group
City
Huntington Beach
State/Province
California
Country
United States
Facility Name
Allergy Associates Medical Group Inc.
City
San Diego
State/Province
California
Country
United States
Facility Name
Institute of Healthcare Assessment Inc.
City
San Diego
State/Province
California
Country
United States
Facility Name
Allergy and Asthma Associates of Santa Clara Valley Research Center
City
San Jose
State/Province
California
Country
United States
Facility Name
Allergy and Asthma Clinical Research Inc.
City
Walnut Creek
State/Province
California
Country
United States
Facility Name
Colorado Asthma and Allergy Research Centers, P.C.
City
Centenniel
State/Province
Colorado
Country
United States
Facility Name
Asthma and Allergy Associates P.C. and Research Center
City
Colorado Springs
State/Province
Colorado
Country
United States
Facility Name
National Jewish Health
City
Denver
State/Province
Colorado
Country
United States
Facility Name
Florida Center for Asthma and Allergy Research
City
Miami
State/Province
Florida
Country
United States
Facility Name
Allergy and Asthma Diagnostic Treatment Center
City
Tallahassee
State/Province
Florida
Country
United States
Facility Name
Partners in Asthma and Allergy Care, P.A.
City
Valrico
State/Province
Florida
Country
United States
Facility Name
Pulmonary Consultants of North Idaho
City
Coeur d'Alene
State/Province
Idaho
Country
United States
Facility Name
Deaconess Clinic Downtown
City
Evansville
State/Province
Indiana
Country
United States
Facility Name
Allergy and Clinical Immunology
City
Bangor
State/Province
Maine
Country
United States
Facility Name
The Brigham and Womens Hospital Inc.
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
North East Medical Research Associates, Inc
City
North Dartmouth
State/Province
Massachusetts
Country
United States
Facility Name
Cardiopulmonary Associates of Missoula
City
Missoula
State/Province
Montana
Country
United States
Facility Name
Pulmonary and Allergy Associates
City
Summit
State/Province
New Jersey
Country
United States
Facility Name
ENT and Allergy Associates
City
Newburgh
State/Province
New York
Country
United States
Facility Name
Wake Forest University
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
New Horizons Clinical Research
City
Cincinatti
State/Province
Ohio
Country
United States
Facility Name
Bernstein Clinical Research Center
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
Allergy, Asthma and Clinical Research Center
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
IPS Research
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
Allergy and Asthma Associates/Oak Street Medical P.C.
City
Eugene
State/Province
Oregon
Country
United States
Facility Name
Allergy Associates Research Center
City
Portland
State/Province
Oregon
Country
United States
Facility Name
Asthma and Allergy Research of New Jersey Inc.
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Asthma and Allergy Research Associates, PA
City
Upland
State/Province
Pennsylvania
Country
United States
Facility Name
Asthma, Nasal Disease and Allergy Research Center of New England
City
Providence
State/Province
Rhode Island
Country
United States
Facility Name
Greenville Pharmaceutical Research
City
Greenville
State/Province
South Carolina
Country
United States
Facility Name
Spartanburg Medical Research
City
Spartanburg
State/Province
South Carolina
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
Country
United States
Facility Name
Allergy and Asthma Research Center, P.A.
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Discovery Clinical Trials, LLC
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Johnston Memorial Hospital
City
Abingdon
State/Province
Virginia
Country
United States
Facility Name
Dr. Kenessey Albert Kórház - Rendelőintézet
City
Balassagyarmat
Country
Hungary
Facility Name
Gyógyír XI Kht ( XI Kerületi Tüdőgondozó)
City
Budapest
Country
Hungary
Facility Name
Margit Kórház
City
Csorna
Country
Hungary
Facility Name
Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza
City
Deszk
Country
Hungary
Facility Name
Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktató Kórház
City
Nyiregyhaza
Country
Hungary
Facility Name
Siofok Varos Korhaz-Rendelointezet
City
Siofok
Country
Hungary
Facility Name
Szarvasi Tüdőgyógyász Kft.
City
Szarvas
Country
Hungary
Facility Name
Men For Care Kft. Százhalom Egészségügyi Központ
City
Szazhalombatta
Country
Hungary
Facility Name
Vas Megyei Markusovszky Lajos Általános, Rehabilitációs és Gyógyfürdő Kórház
City
Szombathely
Country
Hungary
Facility Name
Komárom-Esztergom Megyei Önkormányzat Szent Borbála Kórháza
City
Tatabánya
Country
Hungary
Facility Name
Érd Városi Önkormányzat Szakorvosi Rendelőintézet
City
Érd
Country
Hungary
Facility Name
Prywatny Gabinet Internistyczno - Alergologiczny
City
Bialystok
Country
Poland
Facility Name
10 Wojskowy Szpital Kliniczny z Poliklinika Kliniczny Oddzial Pulmonologiczny
City
Bydgoszcz
Country
Poland
Facility Name
Specjalistyczny Zespol Chorob Pluc i Gruzlicy w Bystrej
City
Bystra
Country
Poland
Facility Name
Medcare NZOZ
City
Gdansk
Country
Poland
Facility Name
All-Med
City
Krakow
Country
Poland
Facility Name
NZOZ Centrum Alergologii prof. Krzysztof Buczylko
City
Lodz
Country
Poland
Facility Name
Poradnia Alergologii i Chorob Pluc SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlicki
City
Lodz
Country
Poland
Facility Name
AlergoTest SC
City
Lublin
Country
Poland
Facility Name
NZOZ Centrum Medyczne Lucyna Andrzej Dymek
City
Strzelce Opolskie
Country
Poland
Facility Name
Alergomed Specjalistyczna Przychodnia Lekarska sp zoo
City
Tarnów
Country
Poland
Facility Name
Barnsley District Hospital
City
Barnsley
Country
United Kingdom
Facility Name
Birmingham Heartlands Hospital
City
Birmingham
Country
United Kingdom
Facility Name
Queens Hospital
City
Burton on Trent
Country
United Kingdom
Facility Name
Woolpit Health Centre
City
Bury St. Edmunds
Country
United Kingdom
Facility Name
Addenbrookes Hospital
City
Cambridge
Country
United Kingdom
Facility Name
Avondale Surgery
City
Chesterfield
Country
United Kingdom
Facility Name
Chesterfield Royal Hospital
City
Chesterfield
Country
United Kingdom
Facility Name
Colchester General Hospital
City
Colchester
Country
United Kingdom
Facility Name
Gartnavel General Hospital
City
Glasgow
Country
United Kingdom
Facility Name
Glenfield Hospital
City
Leicester
Country
United Kingdom
Facility Name
Hammersmith Hospital
City
London
Country
United Kingdom
Facility Name
Morriston Hospital
City
Swansea
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
22541248
Citation
Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, Meyers DA, Bleecker ER. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol. 2012 Aug;130(2):516-22.e4. doi: 10.1016/j.jaci.2012.03.030. Epub 2012 Apr 26.
Results Reference
derived

Learn more about this trial

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

We'll reach out to this number within 24 hrs